JP2003512423A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003512423A5 JP2003512423A5 JP2001532753A JP2001532753A JP2003512423A5 JP 2003512423 A5 JP2003512423 A5 JP 2003512423A5 JP 2001532753 A JP2001532753 A JP 2001532753A JP 2001532753 A JP2001532753 A JP 2001532753A JP 2003512423 A5 JP2003512423 A5 JP 2003512423A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- ixc
- formulas
- iiia
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 description 21
- 239000000203 mixture Substances 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 4
- 230000004913 activation Effects 0.000 description 3
- 102100022641 Coagulation factor IX Human genes 0.000 description 2
- 108010076282 Factor IX Proteins 0.000 description 2
- 108010014173 Factor X Proteins 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960004222 factor ix Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012289 standard assay Methods 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010058046 Post procedural complication Diseases 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16185599P | 1999-10-27 | 1999-10-27 | |
| US60/161,855 | 1999-10-27 | ||
| PCT/US2000/029725 WO2001030333A2 (en) | 1999-10-27 | 2000-10-27 | Tissue factor antagonists and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003512423A JP2003512423A (ja) | 2003-04-02 |
| JP2003512423A5 true JP2003512423A5 (https=) | 2007-12-13 |
Family
ID=22583059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001532753A Withdrawn JP2003512423A (ja) | 1999-10-27 | 2000-10-27 | 組織因子アンタゴニスト及びその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6608066B1 (https=) |
| EP (1) | EP1223921A2 (https=) |
| JP (1) | JP2003512423A (https=) |
| KR (2) | KR20070049251A (https=) |
| CN (1) | CN1390122A (https=) |
| AU (1) | AU784426C (https=) |
| CA (1) | CA2387857A1 (https=) |
| WO (1) | WO2001030333A2 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030109680A1 (en) | 2001-11-21 | 2003-06-12 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
| US5986065A (en) | 1997-03-10 | 1999-11-16 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
| US20060235209A9 (en) | 1997-03-10 | 2006-10-19 | Jin-An Jiao | Use of anti-tissue factor antibodies for treating thromboses |
| US7749498B2 (en) | 1997-03-10 | 2010-07-06 | Genentech, Inc. | Antibodies for inhibiting blood coagulation and methods of use thereof |
| PL343424A1 (en) | 1998-04-10 | 2001-08-13 | Japan Tobacco Inc | Amidine compounds |
| AU2002336920A1 (en) * | 2001-11-02 | 2003-05-12 | Novo Nordisk Health Care Ag | Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis |
| US6858587B2 (en) | 2001-11-02 | 2005-02-22 | Novo Nordisk Pharmaceuticals, Inc. | Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis |
| AP2004003113A0 (en) * | 2002-02-22 | 2004-09-30 | Prophy Med Ab | Use of an inhibitor or antagonist against tissue factor |
| US20040171073A1 (en) * | 2002-10-08 | 2004-09-02 | Massachusetts Institute Of Technology | Compounds for modulation of cholesterol transport |
| WO2004041302A1 (en) * | 2002-11-06 | 2004-05-21 | Novo Nordisk A/S | Pharmaceutical composition comprising a tissue factor antagonist and a blood glucose regulator |
| US8455489B2 (en) * | 2003-11-10 | 2013-06-04 | Exelixis, Inc. | Substituted pyrimidine compositions and methods of use |
| BRPI0509282A (pt) * | 2004-03-30 | 2007-09-18 | Univ California | compostos contendo hidrazida inibidores de cftr e seus usos |
| WO2008030260A2 (en) * | 2005-12-22 | 2008-03-13 | Genentech, Inc. | Treatment of variola viral infections using a tissue factor inhibitor |
| CA2635531C (en) | 2005-12-29 | 2014-06-17 | Lexicon Pharmaceutical Inc. | Multicyclic amino acid derivatives and methods of their use |
| EP2117601A2 (en) | 2006-12-22 | 2009-11-18 | The Regents of the University of California | Macromolecular conjugates of cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof |
| EP2142498A2 (en) | 2007-04-02 | 2010-01-13 | Institute for Oneworld Health | Cftr inhibitor compounds and uses thereof |
| US8236838B2 (en) | 2008-04-21 | 2012-08-07 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
| WO2009131957A2 (en) | 2008-04-21 | 2009-10-29 | Institute For Oneworld Health | Compounds, compositions and methods comprising oxadiazole derivatives |
| US8343976B2 (en) | 2009-04-20 | 2013-01-01 | Institute For Oneworld Health | Compounds, compositions and methods comprising pyrazole derivatives |
| CN101928254B (zh) * | 2010-07-09 | 2012-05-02 | 南京大学 | 苯并三唑衍生物及其制法与用途 |
| CN102690258B (zh) * | 2012-05-29 | 2015-11-25 | 湖北省生物农药工程研究中心 | 含氮杂环亚胺衍生物及其制备方法和用途 |
| CN110133303B (zh) * | 2019-05-13 | 2023-04-07 | 深圳优迪生物技术有限公司 | 凝血酶原时间测定试剂及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0236022B1 (en) | 1986-02-24 | 1994-02-09 | Hitachi, Ltd. | Lubricating composition for plastic working and articles worked by using the same |
| FR2681324B1 (fr) * | 1991-09-18 | 1993-10-29 | Adir Cie | Nouveaux derives de la trimetazidine, leur procede de preparation et les compositions pharmaceutiques les contenant. |
| AU5093593A (en) | 1992-08-28 | 1994-03-29 | Scripps Research Institute, The | Inhibition of tumor metastasis via neutralization of tissue factor function |
| PT833911E (pt) * | 1995-06-07 | 2004-09-30 | Ortho Mcneil Pharm Inc | Anticorpos anti-factor tecidular enxertados com cdr e metodos para a sua utilizacao |
| US6130221A (en) * | 1997-03-05 | 2000-10-10 | Nymox Corporation | Pharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptions |
| US5986065A (en) * | 1997-03-10 | 1999-11-16 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
| ES2339196T3 (es) * | 1997-07-18 | 2010-05-17 | Novo Nordisk Health Care Ag | Uso de fviia o fviiai para el tratamiento de disfuncion endotelial y para la inhibicion de angiogenesis, respectivamente. |
| DE19743435A1 (de) * | 1997-10-01 | 1999-04-08 | Merck Patent Gmbh | Benzamidinderivate |
| AU2826099A (en) * | 1998-03-24 | 1999-10-18 | Novo Nordisk A/S | Heterocyclic compounds regulating clotting |
| EP1115396A4 (en) * | 1998-09-25 | 2002-05-22 | Sunol Molecular Corp | PHARMACEUTICALLY ACTIVE COMPOUNDS, AND METHODS OF USE THEREOF |
| JP2003530819A (ja) | 1999-06-14 | 2003-10-21 | ノボ ノルディスク アクティーゼルスカブ | ＦＶＩＩａ／ＴＦ活性阻害化合物 |
-
2000
- 2000-10-27 US US09/698,673 patent/US6608066B1/en not_active Expired - Fee Related
- 2000-10-27 AU AU12403/01A patent/AU784426C/en not_active Ceased
- 2000-10-27 WO PCT/US2000/029725 patent/WO2001030333A2/en not_active Ceased
- 2000-10-27 KR KR1020077009414A patent/KR20070049251A/ko not_active Ceased
- 2000-10-27 JP JP2001532753A patent/JP2003512423A/ja not_active Withdrawn
- 2000-10-27 CN CN00814765A patent/CN1390122A/zh active Pending
- 2000-10-27 EP EP00973964A patent/EP1223921A2/en not_active Withdrawn
- 2000-10-27 CA CA002387857A patent/CA2387857A1/en not_active Abandoned
- 2000-10-27 KR KR1020027005209A patent/KR20020048977A/ko not_active Abandoned
-
2003
- 2003-05-23 US US10/445,205 patent/US6849617B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003512423A5 (https=) | ||
| WO2005011656A3 (en) | Pyridyl derivatives and their use as therapeutic agents | |
| MA27292A1 (fr) | Procedes et compositions pour le traitement du virus de l'hepatite c | |
| ATE291013T1 (de) | Durch einen omega-thiarest substituierte phenyl- prostaglandin-e-derivate, verfahren zu ihrer herstellung und medikamente die diese als aktiven inhaltsstoff enthalten | |
| WO2005011655A3 (en) | Pyridazine derivatives and their use as therapeutic agents | |
| WO2000049007A8 (en) | Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsin s | |
| SE0102438D0 (sv) | New compounds | |
| AU9189301A (en) | Use of substituted imidazo(1,2-A)pyridine-, imidazo(1,2-A)pyrimidine and imidazo(1,2-A)pyrazine-3-YL-amine derivatives for producing NOS-inhibiting medicaments | |
| DE60215814D1 (de) | Vinylphenyl-derivate als glk-aktivatoren | |
| SE0102300D0 (sv) | Compounds | |
| TNSN06032A1 (en) | Pyridazine derivatives and their use as therapeutic agents | |
| WO2003053330A3 (en) | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer’s disease and conditions associated with glycogen synthase kinase-3 | |
| DE60234577D1 (de) | Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält | |
| SE0001931L (sv) | Metod vid tillverkning av en mall, samt mallen tillverkad därav | |
| CA2445744A1 (en) | Antiviral nucleoside derivatives | |
| CA2407371A1 (en) | Quinazoline derivatives for the treatment of tumours | |
| WO2004094384A3 (en) | (hetero) arylamide 2-hydroxy-3-diaminoalkanes for use in the treatment of alzheimer’s disease | |
| ATE253580T1 (de) | Neue thieno(2,3-d)pyrimidindione, verfahren für ihre herstellung und ihre verwendung in der therapie | |
| JP2002525323A5 (https=) | ||
| JP2003306481A5 (https=) | ||
| WO2001035906A3 (en) | Personal care articles comprising a hydrophilic conditioning agent exhibiting a defined leaching value | |
| DE69431035T2 (de) | 2-Phenyl-3-Azoylbenzothiophene zur Erhöhung der Thrombomodulin Expression | |
| WO2003030886A3 (en) | Allylamides useful in the treatment of alzheimer's disease | |
| EP0992509A3 (en) | Novel macrolide derivatives | |
| DE69530429D1 (de) | Catecholdiether-derivate verwendbar als pharmazeutische mittel |